On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), referencing Amgen’s PROLIA® and XGEVA®, respectively. These approvals make Fresenius the fourth company to receive FDA approval for a pair of denosumab biosimilars, joining Celltrion, Samsung, and Sandoz. Denosumab is a RANK ligand (RANKL)…